Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Blood red petri-dish in the hand of a researcher with bacterial colonies grown on the plate.

Prof Paresh Vyas and his team are investigating haematopoietic stem cells (HSCs) and clonal haematopoiesis (CH), associated with cardiovascular disease and blood cancers. They have been collecting bone marrow samples from otherwise well patients having hip-replacement operations to further understand the mechanisms involved to help develop targeted therapies.

More recently the team have also been studying patients with COVID-19, to understand if CH has an impact on the clinical course of COVID-19. Find out more about this research on the Cancer Research UK Oxford Centre's website.

Similar stories

T cell Immunotherapy animation launched

A new animation explores work by the Chakraverty Group, Vyas Group, and Professor Borrow from the Jenner Institute.

Irene Roberts delivers Ham-Wasserman Lecture

Presented at the American Society of Hematology Annual Meeting, the award and lectureship recognises individuals from outside the United States who have made significant contributions to Haematology.

Asger Jakobsen receives ASH-BSH Abstract Achievement Award

Dr Jakobsen, a Clinical Research Fellow and DPhil student from the Vyas Group has received the award from the American Society of Hematology and the British Society of Haematology.

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing

The biotechnology company builds upon research conducted by Professor Jim Hughes and Prof. James Davies at the MRC Weatherall Institute of Molecular Medicine, and combines 3D genome technology and machine learning to decode the dark matter of the human genome.

KJ Patel appointed new Chief Scientist of CRUK

Alongside his new role at Cancer Research UK, Prof. Patel will continue as the Director of both the MRC Weatherall Institute for Molecular Medicine (MRC WIMM) and the MRC Molecular Haematology Unit (MRC MHU).